Biology-on-Demand Platform

Controllable, reversible, and precise genetic modulation.

The Future of Ocular Pigmentation is Programmable

A programmable, RNA-based platform delivering precise, controllable outcomes through non-surgical genetic modulation.

Request Access to Data Room

Our Platform

Precision Molecule

siRNA assembly

Gene Silencing Engine

TYRP1 mRNA targeting

Controlled Outcome

RISC-mediated cleavage

60%

Target Protein Knockdown

Western blot analysis — McMaster University

No Observed

Adverse Events

Observed in pre-clinical models (McMaster Study). Upcoming NRC studies will further validate dedicated safety endpoints.

Western Blot — TYRP1 KnockdownNDA-Gated

Protein-level validation at McMaster University. Full quantification, replicates, and methodology available under NDA.

Request Data Room Access

One Molecule, Two Markets

A single programmable RNA platform validated across clinical and cosmetic applications — de-risking value creation from the first molecule.

Precision Oncology

Uveal Melanoma Therapy

TYRP1 is selectively expressed in melanoma cells — a high-fidelity target for RNA silencing in metastatic uveal melanoma, an orphan disease with limited treatment options.

Orphan Indication

FDA fast-track eligibility pathway

Biology-on-Demand

Ocular Pigmentation Modulation

The same siRNA mechanism enables non-surgical, reversible ocular pigmentation modulation — the first programmable cosmetic genetic platform with validated 60% target knockdown.

Non-Surgical

Reversible, controllable, precise

Development Pipeline

ES-TO1|TYRP1 Gene

USPTO 64/001,379 — Filed March 10, 2026

Cosmetic

Ocular Pigmentation Modulation

Discovery

Pre-clinical

IND-Enabling

Phase I

Oncology

Uveal Melanoma Therapy

Discovery

Pre-clinical

IND-Enabling

Phase I

IP Portfolio & Program RoadmapNDA-Gated

USPTO 64/001,379 — 20 siRNA sequences targeting TYRP1. Full patent claims, FTO analysis, and detailed development roadmap available under NDA.

Request Data Room Access

Upcoming Milestones

Q2 2026
Lead Candidate Selection (NRC)
H2 2026
Rabbit PoC Study
2027
IND Application Prep

Leadership

Dr. Peter Fenton

MD, Founder & CEO

Physician and entrepreneur leading EyeSciences' clinical strategy and investor relations. Driving the world's first programmable siRNA ocular pigmentation platform from concept to clinic.

Dr. Cass Dedert

PhD, Research Lead

Molecular biologist directing siRNA design, formulation optimization, and pre-clinical research programs at EyeSciences.

Anton Ilin

Strategy & Business Development

Business development strategist translating EyeSciences' pre-clinical milestones into structured commercial assets. Focused on operational execution and preparing the platform for strategic partnerships.

Request Access to Data Room

We share detailed pre-clinical data, IP filings, and financial projections with qualified investors on a confidential basis.

Qualified institutional investors only.